Cemiplimab is a prescription medication used to treat advanced cutaneous squamous cell carcinoma (CSCC). It is a type of immunotherapy, which works by stimulating the body’s own immune system to fight cancer cells. Cemiplimab is a monoclonal antibody that specifically targets the protein PD-1, which is found on the surface of some T-cells. By blocking PD-1, cemiplimab helps to restore the immune system’s ability to fight the cancer. Cemiplimab is administered as an intravenous infusion every 3 weeks until the cancer is no longer responding to the treatment.
Cemiplimab: An Immunotherapy Drug for Specific Cancers
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody used as immunotherapy to treat specific types of cancer. Here's a detailed description of its key characteristics:
Function:
- Immunotherapy: Unlike traditional chemotherapy drugs that directly target and kill cancer cells, cemiplimab works by activating the body's immune system to fight cancer. It specifically blocks a protein called PD-1 (programmed cell death protein 1) on T cells, a type of immune cell. This allows T cells to recognize and attack cancer cells more effectively.
Uses:
Cemiplimab is currently approved by the US Food and Drug Administration (FDA) for the treatment of:
- Metastatic cutaneous squamous cell carcinoma (mCSCC): This is an advanced form of skin cancer that has spread to other parts of the body.
- Merkel cell carcinoma (MCC): This is a rare and aggressive type of skin cancer.
Important Points:
- Targeted therapy: Cemiplimab is a targeted therapy, meaning it specifically targets specific molecules involved in cancer growth and progression, unlike traditional chemotherapy which can affect healthy cells as well.
- Not a first-line treatment: It's typically used for advanced or metastatic cancer that has not responded to other treatments.
- Side effects: Cemiplimab can cause various side effects, including fatigue, rash, diarrhea, constipation, muscle pain, and pneumonitis (inflammation of the lungs). It's crucial to discuss potential side effects with your doctor before starting treatment.
- Close monitoring: Patients receiving cemiplimab require close monitoring by a healthcare professional to manage side effects and assess treatment response.